AdvairThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7

317 records returned

Severe Asthma Attacks in Kids Averted by Fluticasone/Salmeterol ComboEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In asthmatic children, treatment with fluticasone plus salmeterol is associated with fewer serious exacerbations and lower medical costs compared to the use of an inhaled corticosteroid (ICS) plus montelukast. Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2009 Category: Consumer Health News Tags: Allergy & Clinical Immunology Source Type: news

ACAAI: Fluticasone Plus Salmeterol Cuts Exacerbations in Asthma (CME/CE)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
MIAMI BEACH (MedPage Today) -- Researchers reported here that pediatric patients with asthma treated with fluticasone propionate plus salmeterol in a fixed dose combination experienced fewer serious asthma exacerbations and lower costs when compared to the use of inhaled corticosteroids plus montelukast. (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - November 12, 2009 Category: Respiratory Medicine Source Type: news

Beta2-Receptor Polymorphisms in Patients Receiving Salmeterol with or without Fluticasone Propionate.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: The results showed no evidence of a pharmacogenetic effect of beta-receptor variation on salmeterol response. Clinical Trials Registry information available at www.clinicaltrials.gov, i.d. NCT00102882. PMID: 19910613 [PubMed - as supplied by publisher] (Source: American Journal of Respiratory and Critical Care Medicine)
Source: American Journal of Respiratory and Critical Care Medicine - November 12, 2009 Category: Respiratory Medicine Authors: Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, Anderson WH, Emmett AH, Ortega HG Tags: Am J Respir Crit Care Med Source Type: journals

Management of chronic obstructive pulmonary disease: Moving beyond the asthma algorithmEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
For many years, chronic obstructive pulmonary disease (COPD) was considered a disease of fixed airflow obstruction for which there was no good treatment. Out of desperation and frustration, health care providers extrapolated from asthma to COPD, and standard asthma therapy was adopted without evidence for efficacy. In recent years, we have gained a better understanding of the pathophysiologic differences between asthma and COPD, and prospective controlled trials have provided a rationale for therapy. Smoking cessation is critically important, both as primary prevention and as an effective way to slow the decrease in lung f...
Source: Journal of Allergy and Clinical Immunology - November 1, 2009 Category: Allergy & Immunology Authors: Erin Gordon, Stephen C. Lazarus Tags: Clinical reviews in allergy and immunology Source Type: journals

The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: A randomized controlled trialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The relative systemic availabilities of budesonide and fluticasone between patients with severe COPD and healthy subjects were similar. In patients with COPD, a larger fraction of fluticasone was expectorated in the sputum as compared with budesonide.Trial registration number NCT00379028 (Source: Respiratory Research)
Source: Respiratory Research - October 31, 2009 Category: Respiratory Medicine Authors: Chris DalbyThomasz PowlanowskiThomas LarssonLars BorgstromStaffan EdsbackerTim Harrison Source Type: journals

Adherence to inhaled therapy, mortality and hospital admission in COPDEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Adherence to inhaled medication is significantly associated with reduced risk of death and admission to hospital due to exacerbations in COPD. Further research is needed to understand these strong associations. (Source: Thorax)
Source: Thorax - October 28, 2009 Category: Respiratory Medicine Authors: Vestbo, J, Anderson, J A, Calverley, P M A, Celli, B, Ferguson, G T, Jenkins, C, Knobil, K, Willits, L R, Yates, J C, Jones, P W Tags: Epidemiologic studies, Drugs: respiratory system Chronic obstructive pulmonary disease Source Type: journals

Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: ICS therapy decreases inflammation and can attenuate decline in lung function in steroid-naive patients with moderate to severe COPD. Adding LABAs does not enhance these effects. . PMID: 19841453 [PubMed - in process] (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - October 19, 2009 Category: Internal Medicine Authors: Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ, Tags: Ann Intern Med Source Type: journals

Summaries for patients. Effect of treatment with fluticasone with and without salmeterol on airway inflammation and lung function in patients with chronic obstructive pulmonary disease: a randomized trial.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Authors: PMID: 19841438 [PubMed - in process] (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - October 19, 2009 Category: Internal Medicine Tags: Ann Intern Med Source Type: journals

The importance of small airways inflammation control in the course and therapy of bronchial asthmaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Changes in the structure and function of the small airways (< 2 mm diameter) play a major role in airflow limitation in bronchial asthma. Features of cellular inflammation, consisting of an infiltrate rich in lymphocytes and eosinophils, are present in the small airways of patients with asthma. It is suggested that inflammation in the small airways may be responsible for severe asthma and symptoms of nocturnal asthma. It was documented that applied inhaled therapy did not give sufficient control of inflammation in the small airways, because anti-inflammatory medicines were able to penetrate only into the middle bronchi. Fo...
Source: Articles of Advances in Dermatology and Allergology - TERMEDIA publishing house - October 19, 2009 Category: Dermatology Source Type: journals

Can asthma control be achieved?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
International guidelines for asthma management and prevention – GINA 2006 (Global Strategy for Asthma) currently recommend low-dose ICS as a first line therapy for patients with mild persistent asthma (the second step of therapy), and medium-dose of ICS or combination therapy with LABAs as the preferred therapy for moderate asthma (the third step of therapy). Achieving asthma control is a main therapeutic goal. Although combination of ICS and LABA is generally effective pharmacotherapy, many patients fail to achieve partial or full control with available therapies. Experiments have led to the development of a fixed c...
Source: Articles of Advances in Dermatology and Allergology - TERMEDIA publishing house - October 19, 2009 Category: Dermatology Source Type: journals

Salmeterol/fluticasone propionate: Laryngeal candidiasis: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 19, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Add-on salmeterol compared to double dose fluticasone in pediatric asthma: A double-blind, randomized trial (VIAPAED)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In asthmatic children whose symptoms are uncontrolled on standard doses of inhaled corticosteroids (ICS), guidelines recommend to either increase the ICS dose or to add further controller medication, e.g. a long acting ß2-agonist (LABA). The aim of this study was to compare the efficacy and safety of doubling the dose of ICS (fluticasone proprionate FP 200 µg twice daily) with adding a long-acting beta-2 agonist to the ICS (SFC, salmeterol 50 µg/ FP 100 µg twice daily) in children with uncontrolled asthma.Children between 4 and 16 years of age were eligible for this multicenter, randomized, double blind, double dummy, ...
Source: Pediatric Pulmonology - October 11, 2009 Category: Respiratory Medicine Authors: Monika Gappa, Wolfgang Zachgo, Andrea von Berg, Wolfgang Kamin, Catrin Stern-Sträter, Gratiana Steinkamp, VIAPAED Study Group Source Type: journals

Central and peripheral airway sites of nitric oxide gas exchange in copd.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: In COPD, there was normal NO gas exchange in both large and small airways/alveoli and only large airway NO flux was suppressed with F250/S50 but not F100/S50 despite varying extent of emphysema. Peripheral NO must be corrected for axial NO backdiffusion to avoid spurious conclusions. NCT#00568347. PMID: 19820080 [PubMed - as supplied by publisher] (Source: Chest)
Source: Chest - October 8, 2009 Category: Respiratory Medicine Authors: Gelb AF, Flynn Taylor C, Krishnan A, Fraser C, Shinar CM, Schein MJ, Osann K Tags: Chest Source Type: journals

Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: In severe COPD, with very minimal change in hyperinflation or pulmonary mechanics, salmeterol-fluticasone induced a very significant decrease in activity of the chest wall parasternal inspiratory muscle. This may be of practical benefit to reverse the extensive use of the chest wall muscles and alleviate dyspnea in severe COPD. PMID: 19820074 [PubMed - as supplied by publisher] (Source: Chest)
Source: Chest - October 8, 2009 Category: Respiratory Medicine Authors: Easton PA, Hawes HG, Doig CJ, Johnson MW, Yokoba M, Wilde ER Tags: Chest Source Type: journals

Advair HFA (Fluticasone Propionate and Salmeterol) - updated on RxListEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Advair HFA (Fluticasone Propionate and Salmeterol) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 28, 2009 Category: Drugs & Pharmacology Source Type: consumer

ADVAIR (Fluticasone Propionate And Salmeterol) Powder [SmithKline Beecham Corporation]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Sep 23, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - September 23, 2009 Category: Drugs & Pharmacology Source Type: organizations

Inhaled mometasone furoate for the management of refractory oral corticosteroid-dependent asthma: a case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a case study of a 55-year-old white male with severe persistent refractory corticosteroid- dependent asthma receiving inhaled combination therapy with fluticasone propionate 500 microgram and salmeterol 50 microgram twice-daily in addition to 6-week cycles of oral corticosteroid treatment for the previous 7 months. The patient was switched to high-dose mometasone furoate delivered via a dry powder inhaler (660 microgram twice-daily) for 6 weeks. Considerable improvement from baseline in peak expiratory flow, use of rescue medication, and asthma symptoms of coughing and wheezing was observed. The patient discontin...
Source: Cases Journal - September 10, 2009 Category: Journals (General) Source Type: journals

On the superiority of BDP/FF HFA pMDI fixed combination over the free combination of BDP CFC pMDI and FF DPIEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
I read with surprise the article by Huchon et al. where an extra-fine HFA combination of beclomethsaone dipropionate (BDP) and formoterol fumarate (FF) given via a single pressurised metered-dose inhaler (pMDI) was compared with BDP CFC pMDI and FF dry powder inhaler (DPI) given via separate inhalers. The authors suggest that “the synergistic effect of the two drug classes at various cellular types in the lungs can be enhanced through their co-administration and consequent co-deposition, which may be favoured by the extra-fine formulation of the BDP/FF combination”. Firstly, I would like to clarify that the synergisti...
Source: Respiratory Medicine - September 10, 2009 Category: Respiratory Medicine Authors: Alfredo García Arieta Tags: Letters to the Editor Source Type: journals

Childhood evaluation of salmeterol tolerance – A double-blind randomized controlled trialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Carroll WD, Jones PW, Boit P, Clayton S, Cliff I, Lenney W. Childhood evaluation of salmeterol tolerance [ndash] a double-blind randomized controlled trial.Pediatr Allergy Immunol 2009.© 2009 John Wiley & Sons A/S Long acting [beta]2-agonists (LABA) are widely used in children with asthma. Data from adults suggest that there is tachyphylaxis particularly to the bronchoprotective effects of LABA. There are no data in children. To determine whether LABA are subject to tachyphylaxis in school-aged children. Children were eligible for participation if they remained symptomatic on 400 [mu]g of beclometasone dipropionate equiva...
Source: Pediatric Allergy and Immunology - August 29, 2009 Category: Allergy & Immunology Authors: W. D. Carroll, P. W. Jones, P. Boit, S. Clayton, I. Cliff, W. Lenney Source Type: journals

GSK advisory: Warehouse theftEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline has announced that two lots of Advair Diskus medication were stolen earlier this month from the company's distribution facility near Richmond, Virginia. (Source: Drug Topics - Top News)
Source: Drug Topics - Top News - August 27, 2009 Category: Drugs & Pharmacology Source Type: news

GSK advisory: Warehouse theftEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline has announced that two lots of Advair Diskus medication were stolen earlier this month from the company's distribution facility near Richmond, Virginia. (Source: Modern Medicine)
Source: Modern Medicine - August 27, 2009 Category: Journals (General) Source Type: info

GSK advisory: Warehouse theftEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline has announced that two lots of Advair Diskus medication were stolen earlier this month from the company's distribution facility near Richmond, Virginia. (Source: Drug Topics - Legal News)
Source: Drug Topics - Legal News - August 27, 2009 Category: Medical Law Source Type: news

GSK advisory: Warehouse theftEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline has announced that two lots of Advair Diskus medication were stolen earlier this month from the company's distribution facility near Richmond, Virginia. (Source: Drug Topics - Pharmacy News)
Source: Drug Topics - Pharmacy News - August 27, 2009 Category: Pharmaceuticals Source Type: news

[Asthma] Adverse effects of salmeterol in asthma: a neuronal perspectiveEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Increased BDNF concentrations may underly the adverse effects of salmeterol monotherapy on airway responsiveness in asthma. Trial registration number: NCT00736801. (Source: Thorax)
Source: Thorax - August 27, 2009 Category: Respiratory Medicine Authors: Lommatzsch, M, Lindner, Y, Edner, A, Bratke, K, Kuepper, M, Virchow, J C Tags: Asthma, Drugs: respiratory system Source Type: journals

GSK advisory: Advair warehouse theftEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline has announced that two lots of Advair Diskus medication were stolen earlier this month from the company's distribution facility near Richmond, Virginia. (Source: Drug Topics - Top News)
Source: Drug Topics - Top News - August 27, 2009 Category: Drugs & Pharmacology Source Type: news

GSK advisory: Advair warehouse theftEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline has announced that two lots of Advair Diskus medication were stolen earlier this month from the company's distribution facility near Richmond, Virginia. (Source: Modern Medicine)
Source: Modern Medicine - August 27, 2009 Category: Journals (General) Source Type: info

GSK advisory: Advair warehouse theftEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline has announced that two lots of Advair Diskus medication were stolen earlier this month from the company's distribution facility near Richmond, Virginia. (Source: Drug Topics - Legal News)
Source: Drug Topics - Legal News - August 27, 2009 Category: Medical Law Source Type: news

GSK advisory: Advair warehouse theftEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline has announced that two lots of Advair Diskus medication were stolen earlier this month from the company's distribution facility near Richmond, Virginia. (Source: Drug Topics - Pharmacy News)
Source: Drug Topics - Pharmacy News - August 27, 2009 Category: Pharmaceuticals Source Type: news

GSK Advisory: Warehouse TheftEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
RESEARCH TRIANGLE PARK, N.C., Aug. 24 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) is advising that two lots of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) medication were stolen on August 2 from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 25, 2009 Category: Pharmaceuticals Source Type: news

GSK Advisory: Warehouse TheftEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline (NYSE: GSK) is advising that two lots of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) medication were stolen on August 2 from the company's distribution facility near Richmond, Virginia. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - August 24, 2009 Category: Pharmaceuticals Source Type: news

ADVAIR HFA (Fluticasone Propionate And Salmeterol) Aerosol, Metered [SmithKline Beecham Corporation]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Aug 24, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 24, 2009 Category: Drugs & Pharmacology Source Type: organizations

Advair Diskus (Fluticasone Propionate) - updated on RxListEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Advair Diskus (Fluticasone Propionate) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2009 Category: Drugs & Pharmacology Source Type: consumer

Prevalence and Progression of Osteoporosis in Patients With COPD. Results From TORCH.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Osteoporosis is highly prevalent in patients with COPD, irrespective of gender. In the TORCH study, no significant effect on BMD was detected for inhaled corticosteroid therapy compared with placebo. PMID: 19581353 [PubMed - as supplied by publisher] (Source: Chest)
Source: Chest - July 5, 2009 Category: Respiratory Medicine Authors: Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B Tags: Chest Source Type: journals

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: In the TORCH study, SFC reduced moderate-to-severe exacerbations and improved health status and FEV1 across GOLD stages. Treatment with SFC may be associated with reduced mortality compared with placebo in patients with GOLD stage II disease. The effects were similar to those reported for the study as a whole. Thus, SFC is an effective treatment option for patients with GOLD stage II COPD.Trial registrationClinicaltrial.gov registration NCT00268216; Study number: SCO30003 (Source: Respiratory Research)
Source: Respiratory Research - June 29, 2009 Category: Respiratory Medicine Authors: Christine JenkinsPaul JonesPeter CalverleyBartolome CelliJulie AndersonGary FergusonJulie YatesLisa WillitsJorgen Vestbo Source Type: journals

Inhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and futureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Inhaled corticosteroid (ICS) therapy in combination with long-acting β-adrenergic agonists represents the most important treatment for chronic airways diseases such as asthma and chronic obstructive pulmonary disease (COPD). ICS therapy forms the basis for treatment of asthma of all severities, improving asthma control, lung function and preventing exacerbations of disease. Use of ICS has also been established in the treatment of COPD, particularly symptomatic patients, who experience useful gains in quality of life, likely from an improvement in symptoms such as breathlessness and in reduction in ...
Source: European Journal of Clinical Pharmacology - June 26, 2009 Category: Drugs & Pharmacology Tags: European Journal of Clinical Pharmacology Source Type: journals

FDA Safety Changes: Advair Diskus, Orap, RocephinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has approved safety labeling revisions for fluticasone propionate and salmeterol xinafoate inhalation powder, pimozide tablets, and ceftriaxone sodium injection. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 28, 2009 Category: Consumer Health News Tags: Pharmacist Source Type: news

Adherence and persistence with omalizumab and fluticasone/salmeterol within a managed care populationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Allergy and Asthma Proceedings)
Source: Allergy and Asthma Proceedings - May 25, 2009 Category: Allergy & Immunology Authors: Broder, Michael S.Chang, Eunice Y.Ory, CaronKamath, TripthiSapra, Sandhya Tags: Original Articles Source Type: journals

Salmeterol/fluticasone propionate: asthma-related QOL benefitsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 20, 2009 Category: Health Management Tags: Research article Source Type: journals

Salmeterol/fluticasone propionate: asthma-related QOL benefits.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Page: 10 (Source: PharmacoEconomics & Outcomes News)
Source: PharmacoEconomics & Outcomes News - May 19, 2009 Category: Drugs & Pharmacology Tags: HTML Source Type: journals

Salmeterol/fluticasone propionate: Achilles tendonitis (first report) following inhalation in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - May 7, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Salmeterol/fluticasone propionate: Achilles tendonitis (first report) following inhalation in an elderly patient: case report.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Page: 34 (Source: Reactions Weekly)
Source: Reactions Weekly - May 3, 2009 Category: Drugs & Pharmacology Tags: HTML Source Type: journals

Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: ICS/LABA combination treatment was used as initial therapy in 55.2% of children with mild to moderate asthma in this claims database population, contrary to the recommendations of current asthma treatment guidelines. The FDA advisory and black box warning for LABA use had little observed impact on the number of single-entity ICS claims. PMID: 19539106 [PubMed - in process] (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - April 30, 2009 Category: Drugs & Pharmacology Authors: Friedman HS, Eid NS, Crespi S, Wilcox TK, Reardon G Tags: Clin Ther Source Type: journals

Salmeterol/fluticasone reduces inflammatory mediators IL-8 and MMP-9 in COPDEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Treatment with a combination of salmeterol and fluticasone results in a significant reduction in inflammatory mediators in chronic obstructive pulmonary disease patients compared with treatment with tiotropium alone, research shows. (Source: MedWire News - Respiratory)
Source: MedWire News - Respiratory - April 27, 2009 Category: Respiratory Medicine Source Type: news

Adolescents and asthma: Why bother with our meds?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Adherence was poor. Examining and acknowledging health beliefs of older teens in the context of their complicated lives might facilitate discussions about self-management. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - April 22, 2009 Category: Allergy & Immunology Authors: David R. Naimi, Tovia G. Freedman, Kenneth R. Ginsburg, Daniel Bogen, Cynthia S. Rand, Andrea J. Apter Tags: Asthma and lower airway disease Source Type: journals

Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthmaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Exercise is a common trigger in children with persistent asthma and inhaled corticosteroids have been shown to effectively treat clinical manifestations of persistent asthma, including protection from decrements in lung function caused by exercise. The goal of this study was to evaluate the effectiveness of fluticasone propionate/salmeterol 100/50 mcg compared with fluticasone propionate 100 mcg for the prevention of airflow limitation triggered by standardized exercise challenge in pediatric and adolescent patients with persistent asthma.Multicenter, randomized, double-blind, parallel group trial of 248 subjects with pers...
Source: Pediatric Pulmonology - April 20, 2009 Category: Respiratory Medicine Authors: David Pearlman, Paul Qaqundah, Jonathan Matz, Steven W. Yancey, David A. Stempel, Hector G. Ortega Source Type: journals

Budesonide/formoterol tops salmeterol/fluticasone propionate in asthmaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 10, 2009 Category: Health Management Tags: Research article Source Type: journals

Budesonide/formoterol tops salmeterol/fluticasone propionate in asthma.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Page: 7 (Source: PharmacoEconomics & Outcomes News)
Source: PharmacoEconomics & Outcomes News - April 7, 2009 Category: Drugs & Pharmacology Tags: HTML Source Type: journals

Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of lifeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - April 6, 2009 Category: Allergy & Immunology Authors: Edin, Heather M.Andersen, Leslie B.Schoaf, LynneScott-Wilson, Catherine A.Ho, Shu-YenOrtega, Hector G. Tags: ORIGINAL ARTICLES: INTERVENTION Source Type: journals

Health News of the DayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day.Age-related mental decline starts in the late-20s, dips in memory became apparent around age 37. Indicators of a person's accumulated knowledge (vocabulary and general knowledge) improve with age. Mental functions - abstract reasoning, mental speed and puzzle-solving - started to dull as early as age 27 http://bit.ly/vMq3iAnimal allergy cases are increasing, as are human allergy cases: Ten percent of dogs develop allergies h...
Source: Clinical Cases and Images - April 3, 2009 Category: Journals (General) Tags: Health News of the Day Source Type: info

Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: The most cost-effective strategy in moderate-to-severe COPD depends on how much society is willing to pay to achieve health improvements. When treatment with as-needed short-acting bronchodilator use does not provide adequate control, salmeterol or SFC would be the drug of choice depending on WTP. PMID: 19355795 [PubMed - in process] (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 1, 2009 Category: Health Management Authors: Oba Y Tags: Am J Manag Care Source Type: journals